February 25, 2005
This study, presented here by G. van den Brande from the University of California-San Diego and colleagues, sought to establish whether lopinavir/ritonavir (LPV/r, Kaletra) -- a PI that is highly protein bound -- can lower CNS viral load levels in patients even when used as a single agent as part of initial therapy.
Thirteen participants enrolled in the study and began taking lopinavir/ritonavir alone for 3 weeks. Cerebrospinal fluid (CSF) sampling was done at baseline and at 3 weeks in 10 subjects.
At the start of the study, the HIV-RNA level in the plasma was 5.20 log, and in CSF 3.63 log -- a commonly observed 1 to 2 log difference between plasma and CSF. In paired plasma and CSF samples, lopinavir/ritonavir monotherapy was effective in lowering HIV-RNA levels in both compartments, with reductions of 1.7 log and 1.4 log, respectively. Interestingly, patients with more advanced HIV disease (based on higher viral loads and lower CD4+ cell counts) experienced a more rapid decline in CSF HIV RNA.
This small study has important implications for the ongoing development of lopinavir/ritonavir and other boosted PIs as single-agent therapies, either as initial treatment or as maintenance therapy. The data suggest that CNS penetration of antiretroviral agents may not be essential in the prevention of AIDS-related dementia and other neurologic complications of HIV. In addition, the data provide pathophysiologic support for the dramatic decline in AIDS dementia in the current treatment era, a reduction that has occurred with all therapies regardless of their CNS penetration.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.